AI-generated summary
The authors randomized 46 patients with breast cancer-related lymphedema to 904 nm laser, 650 nm laser, or sham treatment. No significant between-group differences were found in lymphatic transport or fluid-related outcomes. A site-specific reduction in upper-lateral shear wave velocity was seen with 904 nm laser versus 650 nm, which the authors describe as exploratory.
- Participants
- 46
- Who or what was studied
- Patients with breast cancer-related lymphedema
- Wavelengths
- 904, 650 nm
- Limits stated in the abstract
- The authors state the findings are limited and exploratory, the study is underpowered, and longer follow-up with prespecified primary outcomes is needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 904 nm, 650 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Laser, Randomized controlled trial, Wavelength, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.